FDA Clears Emerging Cardiovascular Point-of-Care Ultrasound Platform
Combining four CAD modules for valvular pathologies with a variety of automated measurements, the AI-enabled AISAP Cardio ultrasound system reportedly facilitates up to a 90 percent accuracy rate in detecting common cardiac conditions.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the AISAP Cardio, a cloud-based, point-of-care ultrasound (POCUS) system that may enable early detection for a variety of cardiac conditions.1
Offering automated analyses and reports, the AISAP Cardio platform has four computer-assisted diagnosis (CAD) modules for valvular pathologies, according to AISAP, the developer of the POCUS system. Trained on over 24 million echocardiography video clips, the AISAP Cardio platform provides automated measurements for cardiac structural functional parameters, ranging from left ventricle ejection fraction (LVEF) and right ventricular fractional area change (RV FAC) to inferior vena cava (IVC) diameter.
AISAP notes that recently published prospective research showed that use of the AISAP Cardio platform led to management changes in one-third of patients.2 For clinicians with basic ultrasound skills, AISAP maintained that AISAP Cardio has up to a 90 percent accuracy rate in assessing common cardiac structural and functional parameters.1
Smadar Kort, M.D., said the AISAP Cardio platform, which will be commercially available on September 1, has “game-changer” potential.
“We know that structural heart disease and heart failure are the leading causes of hospitalization and morbidity in the U.S. Enabling a wide variety of qualified physicians to quickly and accurately diagnose these conditions at the bedside could lead to earlier detection and treatment, and better patient outcomes, as well as greater efficiencies and cost savings to health systems, while ultimately saving countless lives,” noted Dr. Kort, the system director of non-invasive cardiac imaging at Stony Brook Medicine in Stony Brook, N.Y.
References
1. AISAP. AISAP’s CARDIO AI-powered point-of-care ultrasound diagnostic assessment software receives FDA clearance. Business Wire. Available at: https://www.businesswire.com/news/home/20240822701346/en/AISAP%E2%80%99s-CARDIO-AI-powered-Point-of-Care-Ultrasound-Diagnostic-Assessment-Software-Receives-FDA-Clearance . Published August 22, 2024. Accessed August 22, 2024.
2. Fisher L, Yarkoni Y, Faierstein K, et al. Enhancing handheld point-of-care echocardiography with artificial intelligence: a prospective clinical trial. J Am Coll Cardio. 2024;83(13):2344.
Emerging AI Software for Prostate MRI Offers 95 Percent Sensitivity for csPCa
February 28th 2025In a multicenter study involving over 1,000 patients, a deep learning software offered comparable sensitivity and specificity for Gleason grade group > 2 tumors in comparison to radiologist interpretation.
Can CT-Based AI Help Predict Renal Function Decline After Radioligand Therapy for mCRPC?
February 25th 2025In patients who had at least four cycles of 177Lu-PSMA-I&T for mCRPC, new research shows that a 10 percent or greater decrease in total kidney volume on CT at six months has a 90 percent AUC for predicting estimated glomerular filtration rates (eGFRs) of 30 percent or greater at one year.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Study Assesses Potential of Seven-Minute AI-Enhanced 3T MRI of the Shoulder
February 20th 2025Researchers found that the use of seven-minute threefold parallel imaging-accelerated deep learning 3T MRI had 89 percent sensitivity for supraspinatus-infraspinatus tendon tears and 93 percent sensitivity for superior labral tears.
